Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Curevac N.V.
(NQ:
CVAC
)
2.520
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Curevac N.V.
< Previous
1
2
3
Next >
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
April 24, 2024
Via
ACCESSWIRE
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
April 24, 2024
Via
ACCESSWIRE
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
April 24, 2024
Via
ACCESSWIRE
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
April 18, 2024
Via
ACCESSWIRE
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
April 16, 2024
Via
ACCESSWIRE
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
November 14, 2023
Via
ACCESSWIRE
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
April 04, 2024
Via
ACCESSWIRE
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
January 05, 2024
Via
ACCESSWIRE
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
December 19, 2023
Via
ACCESSWIRE
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
November 01, 2023
Via
ACCESSWIRE
3 Stocks to Buy For the COVID Resurgence
September 06, 2023
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting
Via
MarketBeat
Exposures
COVID-19
Product Safety
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
August 17, 2023
Via
ACCESSWIRE
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
August 01, 2023
Via
ACCESSWIRE
CureVac Announces Update to the Management Team
July 14, 2023
Via
ACCESSWIRE
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights
July 13, 2023
Via
ACCESSWIRE
CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma
June 20, 2023
Via
ACCESSWIRE
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board
June 20, 2023
Via
ACCESSWIRE
CureVac Announces Voting Results of General Meeting
June 19, 2023
Via
ACCESSWIRE
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update
May 30, 2023
Via
ACCESSWIRE
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech
May 19, 2023
Via
ACCESSWIRE
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK
May 08, 2023
Via
ACCESSWIRE
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update
April 25, 2023
Via
ACCESSWIRE
CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023
April 18, 2023
Via
ACCESSWIRE
CureVac Announces Voting Results of Extraordinary General Meeting
March 28, 2023
Via
ACCESSWIRE
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares
February 10, 2023
Via
ACCESSWIRE
CureVac Announces Proposed Public Offering of Common Shares
February 07, 2023
Via
ACCESSWIRE
CureVac Welcomes Myriam Mendila as New Chief Development Officer
February 01, 2023
Via
ACCESSWIRE
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis(R)
January 31, 2023
Via
ACCESSWIRE
CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs
January 30, 2023
Via
ACCESSWIRE
CureVac Appoints Alexander Zehnder as CEO From April 1, 2023
January 09, 2023
Via
ACCESSWIRE
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.